{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.25","value":"4.8"},{"groupId":"OG001","spread":"2.44","value":"4.6"},{"groupId":"OG002","spread":"2.53","value":"4.6"},{"groupId":"OG003","spread":"2.25","value":"4.7"}]}],"title":"Fatigue Now"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.12","value":"4.7"},{"groupId":"OG001","spread":"2.40","value":"4.7"},{"groupId":"OG002","spread":"2.53","value":"4.7"},{"groupId":"OG003","spread":"2.24","value":"4.7"}]}],"title":"Usual Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.17","value":"5.5"},{"groupId":"OG001","spread":"2.54","value":"5.6"},{"groupId":"OG002","spread":"2.60","value":"5.4"},{"groupId":"OG003","spread":"2.43","value":"5.3"}]}],"title":"Worst Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.95","value":"4.3"},{"groupId":"OG001","spread":"2.42","value":"4.1"},{"groupId":"OG002","spread":"2.60","value":"4.3"},{"groupId":"OG003","spread":"2.17","value":"4.4"}]}],"title":"BFI Interference"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"}],"units":"Participants"}],"description":"To compare the effects of the 3 different epoetin alfa dosing schedules and a darbepoetin alfa schedule. Brief Fatigue Inventory (BFI) consist of 3 single-item numeric analogue scales on a scale of 0 to 10; and an interference scale formed by 6 single-item numeric scales on a scale of 0 to 10. Higher scores indicate fatigue as bad as you can imagine for fatigue now, usual fatigue and worse fatigue; and completely interferes for BFI interference. Average scores across all time points for fatigue now, usual fatigue, worst fatigue and BFI interference subscale were calculated.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive Epoetin alfa 40,000 units subcutaneously every week for 15 weeks (15 doses)","id":"OG000","title":"Epoetin Alfa - 40k Weekly"},{"description":"Patients receive Epoetin alfa 80,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG001","title":"Epoetin Alfa - 80k Every 3 Weeks"},{"description":"Patients receive Epoetin alfa 120,000 units subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG002","title":"Epoetin Alfa - 120k Every 3 Weeks"},{"description":"Patients receive Darbepoetin alfa 500 micrograms (mcg) subcutaneously every 3 weeks for 15 weeks (5 doses)","id":"OG003","title":"Darbepoetin Alfa - 500 mcg Every 3 Weeks"}],"paramType":"MEAN","populationDescription":"All patients that were evaluable per protocol with QOL data.","reportingStatus":"POSTED","timeFrame":"Weeks 4, 7, 10, 13 and 16","title":"Quality of Life as Measured by Brief Fatigue Inventory Overall All Follow-up Evaluations","type":"SECONDARY","unitOfMeasure":"units on a scale"}